UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
Commission File Number: 000-15888
(Check One): [ ] Form 10-KSB [ ] Form 20-F [ ] Form 11-K
[X] Form 10-QSB [ ] Form N-SAR [ ] Form N-CSR
For Period Ended: June 30, 2007
[ ] Transition Report on Form 10-K and Form 10-KSB
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q and Form 10-QSB
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: ____________________
Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
If the notification relates to a portion of the filing
checked above, identify the item(s) to which the notification
relates: ________________________________________________
PART I
REGISTRANT INFORMATION
Full Name of Registrant: IGENE BIOTECHNOLOGY, INC.
Former Name if Applicable: NA
Address of Principal Executive Office: 9110 RED BRANCH ROAD
City, State and Zip Code: COLUMBIA, MARYLAND 21045-2024
-1-
PART II
RULES 12b-25(b) AND (c)
If the subject report could not be filed without
unreasonable effort or expense and the registrant seeks relief
pursuant to Rule 12b-25(b), the following should be completed.
(Check box if appropriate.)
(a) The reasons described in reasonable detail in
Part III of this form could not be eliminated
without unreasonable effort or expense;
(b) The subject annual report, semi-annual report,
transition report on Form 10-K, Form 20-F,
Form 11-K, Form N-SAR or Form N-CSR, or portion
thereof, will be filed on or before the
[ ] fifteenth calendar day following the prescribed
due date; or the subject quarterly report or
transition report on Form 10-Q, or portion
thereof will be filed on or before the fifth
calendar day following the prescribed due date;
and
(c) The accountant's statement or other exhibit
required by Rule 12b-25(c) has been attached if
applicable.
PART III
NARRATIVE
State below in reasonable detail the reasons why the Forms
10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or
portion thereof, could not be filed within the prescribed time
period.
Additional time will be needed for the Registrant to
complete the preparation of its Quarterly Report on Form 10-
QSB (the "Form 10-QSB") for the quarter ended June 30, 2007.
The Registrant was informed on August 10, 2007 by its
independent accountant, J.H. Cohn ("Cohn"), in connection
with its review of Form 10-QSB that they required an
independent valuation of warrants associated with certain
debt. The Registrant will require additional time to file
the Form 10-QSB in order to prepare the warrant valuation
and determine whether any corresponding revaluation of
related debt instruments is material. Prior to completion
of this determination, the Registrant is unable to file and
certify the Form 10-QSB.
Based upon its current schedule, the Registrant
anticipates that it will not be in a position to file its
Form 10-QSB by the 5th calendar day following the prescribed
due date of the Form 10-QSB.
-2-
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to
this notification.
Edward J. Weisberger (410) 997-2599
___________________________________________________________
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13
or 15(d) of the Securities Exchange Act of 1934 or Section
30 of the Investment Company Act of 1940 during the
preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed?
If answer is no, identify report(s).
[X] Yes [ ] No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last
fiscal year will be reflected by the earnings statements to
be included in the subject report or portion thereof?
[X] Yes [ ] No
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state
the reasons why a reasonable estimate of the results cannot
be made.
The Registrant cannot provide a reasonable estimate until a
valuation is prepared, nor be sure if a significant change
will result.
Igene Biotechnology, Inc.
____________________________________________
(Name of Registrant as Specified in Charter)
Has caused this notification to be signed on its behalf by
the undersigned thereunto duly authorized.
Date: August 14, 2007 By: /s/ EDWARD J. WEISBERGER
___________________________
Edward J. Weisberger
Chief Financial Officer